ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1408

Monitoring Patients with Systemic Lupus Erythematosus in Clinical Practice: Have You Already Checked the Vaccination Status in Your Patients?

Olga Malysheva, Jean-Philipp Ivanov, Sybille Arnold and Christoph G. Baerwald, Rheumatology, University Hospital, Leipzig, Germany

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: systemic lupus erythematosus (SLE) and vaccines

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus: Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose: : Infection is one of the main causes of morbidity and increased mortality in patients with systemic lupus erythematodes (SLE). Information about vaccination history and updating vaccinations on a regular basis is an economical way to avoid complications of various infections. Ideally vaccinations should be done prior to starting immunosuppressive treatment.  Influenza, pneumococcal and tetanus vaccines are safe and do not lead to SLE flares while the majority of patients develop protective antibodies. Recommendations for hepatitis B and varicella herpes zoster (VZV) vaccination have not yet been validated in SLE patients. The purpose of study was to assess the vaccination rates against common infections and to determine the incidence of hepatitis B and VZV infections in patients with SLE attending a rheumatology outpatient clinic. 

Methods: Data collected included age, duration of disease and treatment (systemic corticosteroids, methotrexate, azathioprine, hydroxychloroquine). According to the recommendations for vaccination in patients with rheumatic diseases derived from The European League against Rheumatism (EULAR) and the German Robert Koch Institute for Infection Control vaccination history was taken for MMR (measles, mumps and rubella), poliomyelitis, pertussis, diphtheria, influenza, human papillomavirus, hepatitis A, hepatitis B, tetanus, meningococcal and pneumococcal vaccines. A simple questionnaire was designed and 68 SLE patients were asked to provide their vaccination records. Patients were also tested for hepatitis B (anti-HBc, anti-HBs) and VZV (IgG) status.

Results: 95.6 % of SLE patients presented a vaccination card. Of interest, 75 % patients did not receive the influenza vaccine in the previous year. Only 12 patients (19 %) in total and 30 % in the age group > 60 years have ever received the pneumococcal vaccination. The vaccination rate for tetanus (combined vaccination with diphtheria and pertussis) was 51 %. For the remaining vaccinations the following picture emerged: vaccination was complete for 66 % against poliomyelitis, 11.8 % for hepatitis A, 1.5 % for meningococcus, 2.6 % for MMR. Only 1.6 % of SLE patients were vaccinated against human papillomavirus (only 12.5 % of the patients < 27 years).  Patients with SLE do not have an increased incidence of hepatitis B and we did not detect any patient with an active hepatitis B.  Only 14.7 % patients with SLE had a vaccination against hepatitis B. 2 SLE patients (3.6 %) exhibited an abnormal hepatitis serology (increase of anti-HBc + anti-HBs-Titre, or anti-HBc) and only one of them had a moderate increase of liver enzymes. 97 % SLE patients were positive for VZV IgG and 23 SLE patients (33.8 %) had a history of VZV infection with postherpetic neuralgia. Therefore, 60 % of SLE patients may be considered for herpes zoster vaccination; however, no patient was vaccinated against VZV.

Conclusion: In SLE patients with stable disease the vaccination rate was low. More careful monitoring of SLE patients concerning vaccination is necessary. In particular with new therapies being directed against B-lymphocytes a timely update of the vaccination status is mandatory for every individual patient with SLE.


Disclosure:

O. Malysheva,
None;

J. P. Ivanov,
None;

S. Arnold,
None;

C. G. Baerwald,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/monitoring-patients-with-systemic-lupus-erythematosus-in-clinical-practice-have-you-already-checked-the-vaccination-status-in-your-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology